Investors

Founded in 2002, Conkwest Incorporated develops cell based products for cancer and life threatening viral infections that are intended to improve quality of life while delivering excellence, value and maximum return.

Conkwest’s core business consists of a cell line platform that can be applied to the drug discovery, development and manufacturing of monoclonal antibody products by third parties; and preclinical and clinical development of NK-92 based cell lines for multiple therapeutic applications.

Investor Relations

Jody Cain
LHA
T: 310.691.7100
F: 310.691.7150
[email protected]

Press Releases

Jan 6, 2015

Conkwest, Sorrento And NantWorks Announce Presentation At The 33rd Annual J. P. Morgan Healthcare Conference By Dr. Patrick Soon-Shiong

Dec 29, 2014

Conkwest Appoints Robert Rosen and Henry Ji to its Board of Directors

Dec 24, 2014

Conkwest Announces $50M in Strategic Investment and Appoints Nantworks Founder, Dr. Patrick Soon-Shiong as Co-Chairman of the Board

Dec 19, 2014

Sorrento and Conkwest Announce Exclusive Global Collaboration Developing Next Generation Cancer Immunotherapy with “Off-the-Shelf” Chimeric Antigen Receptor–Tumor Attacking Natural Killer (CAR-TNK™) Cell Lines

The information on this Website including any investor downloads is not an offer to sell or solicitation of an offer to buy any interest in the company. Please review the Legal Notice before accessing investor downloads.